Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Novavax, Inc. before investing.

In this article, we go over a few key elements for understanding Novavax, Inc.’s stock price such as:

• Novavax, Inc.’s current stock price and volume
• Why Novavax, Inc.’s stock price changed recently
• Upgrades and downgrades for NVAX from analysts
• NVAX’s stock price momentum as measured by its relative strength

About Novavax, Inc. (NVAX)

Before we jump into Novavax, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Want to learn more about Novavax, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Novavax, Inc..

Novavax, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Novavax, Inc.’s stock price was $7.320.

Novavax, Inc. is down 1.61% from its previous closing price of $7.440.

During the last market session, Novavax, Inc.’s stock traded between $7.215 and $7.490. Currently, there are approximately 163.28 million shares outstanding for Novavax, Inc..

Novavax, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Novavax, Inc. Stock Price History

Novavax, Inc.’s (NVAX) price is currently down 22.29% so far this month.

During the month of July, Novavax, Inc.’s stock price has reached a high of $10.120 and a low of $7.150.

Over the last year, Novavax, Inc. has hit prices as high as $11.970 and as low as $6.200. Year to date, Novavax, Inc.’s stock is up 8.93%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Novavax, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Novavax, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Novavax, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Novavax, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Novavax, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Novavax, Inc. (NVAX) by visiting AAII Stock Evaluator.

Relative Price Strength of Novavax, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Novavax, Inc. has a weighted four-quarter relative price strength of -3.26%, which translates to a Momentum Score of 42 and is considered to be Average.

Want to learn more about how Novavax, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Novavax, Inc. Stock Price: Bottom Line

As of July 31, 2026, Novavax, Inc.’s stock price is $7.320, which is down 1.61% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Novavax, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.